Y-BOX BINDING PROTEIN YB-1 IDENTIFIES HIGH-RISK PRIMARY BREAST CANCER PATIENTS BENEFITING FROM RAPIDLY CYCLED TANDEM HIGH-DOSE ADJUVANT CHEMOTHERAPY

被引：0
|
作者：
Gluz, O. [1 ]
Mengele, K.
Schmitt, M. [2 ]
Kates, R.
Diallo-Danebrock, R. [3 ]
Royer, H. [4 ]
Eckstein, N. [4 ]
Mohrmann, S. [3 ]
Nitz, U. [1 ]
Harbeck, N. [5 ]
机构：
[1] Breast Clin Niederrhein, W German Study Grp, Monchengladbach, Germany
[2] Tech Univ Munich, Clin Gynaecol & Obstet, Munich, Germany
[3] Univ Duesseldorf, Dusseldorf, Germany
[4] CAESAR, Bonn, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Frauenklin, D-8000 Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：55 / 55
页数：1
相关论文
共 50 条
  • [1] Y-Box binding protein YB-1 identifies high-risk primary breast cancer patients benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy
    Schmitt, Manfred
    Gluz, Oleg
    Mengele, Karin
    Nitz, Ulrike
    Royer, Hans-Dieter
    Harbeck, Nadia
    CANCER RESEARCH, 2009, 69
  • [2] Y-Box-Binding Protein YB-1 Identifies High-Risk Patients With Primary Breast Cancer Benefiting From Rapidly Cycled Tandem High-Dose Adjuvant Chemotherapy
    Gluz, Oleg
    Mengele, Karin
    Schmitt, Manfred
    Kates, Ronald
    Diallo-Danebrock, Raihana
    Neff, Frauke
    Royer, Hans-Dieter
    Eckstein, Niels
    Mohrmann, Svjetlana
    Ting, Evelyn
    Kiechle, Marion
    Poremba, Christopher
    Nitz, Ulrike
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6144 - 6151
  • [3] Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to a adjuvant chemotherapy in breast cancer
    Huang, JX
    Tan, PH
    Li, KB
    Matsumoto, K
    Tsujimoto, M
    Bay, BH
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (03) : 607 - 613
  • [4] High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients
    Bertuzzi, A
    Gullo, G
    Rimassa, L
    Castagna, L
    Santoro, A
    ANNALS OF ONCOLOGY, 2006, 17 (04) : 719 - 720
  • [5] Phosphorylated YB-1 (Y-box binding protein 1) as a biomarker of poor prognosis in patients with breast cancer
    Casimiro, S.
    Bettencourt, M.
    Fernandes, A.
    Pacheco, T. R.
    Maia-Matos, M.
    Costa, A. L.
    Abreu, C.
    Alves, A.
    Correia, L.
    Costa, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S198 - S198
  • [6] High-dose chemotherapy for high-risk primary breast cancer
    Peters, WP
    Dansey, R
    Klein, J
    Berry, D
    ADJUVANT THERAPY OF CANCER VIII, 1997, 8 : 117 - 122
  • [7] High-dose chemotherapy in high-risk primary breast cancer
    Schmid, P
    Possinger, K
    ONKOLOGIE, 2002, 25 (02): : 112 - 120
  • [8] YB-1 protein correlates with high-risk tumor characteristics and response to high dose chemotherapy in breast cancer.
    Gluz, O.
    Harbeck, N.
    Kates, R. E.
    Schmitt, M.
    Mengele, K.
    Royer, H-D
    Eckstein, N.
    Svjetlana, M.
    Ting, E.
    Poremba, C.
    Nitz, U.
    Diallo-Danebrock, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S136 - S136
  • [9] Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases
    Ferreira, A. R.
    Bettencourt, M.
    Alho, I.
    Costa, A. L.
    Sousa, A. R.
    Mansinho, A.
    Abreu, C.
    Pulido, C.
    Macedo, D.
    Vendrell, I.
    Pacheco, T. R.
    Costa, L.
    Casimiro, S.
    JOURNAL OF BONE ONCOLOGY, 2017, 6 : 16 - 21
  • [10] End of high-dose chemotherapy for high-risk breast cancer patients?
    Tuma, Rabiya S.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (09) : 618 - U3
12345